Latest news
GPCR SWOT Analysis: Financial Challenges and Opportunities Revealed in 10-Q Filing - GuruFocusGuruFocus · Sat, 08 Aug 2026 06:32:50 GMTStructure Therapeutics Chief Commercial Officer John Joseph Berrios files initial beneficial ownership statement - BitgetBitget · Fri, 07 Aug 2026 20:56:15 GMTStructure Therapeutics (GPCR) awards options and RSUs to its CCO - Stock TitanStock Titan · Fri, 07 Aug 2026 20:09:08 GMTStructure Therapeutics Inc. (GPCR) files initial Form 3 for CCO - Stock TitanStock Titan · Fri, 07 Aug 2026 20:07:09 GMTStructure Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 23:41:33 GMTStructure Therapeutics Q2 net loss widens on higher R&D costs - TradingViewTradingView · Thu, 06 Aug 2026 20:45:51 GMTStructure Therapeutics posts $106.2M Q2 net loss, $1.34B cash; doses first patients in Phase 3 aleniglipron - TradingViewTradingView · Thu, 06 Aug 2026 20:35:29 GMTStructure Therapeutics Inc. 2026: Revenue ($107.41M), Net income ($106.16M), EPS ($0.49) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:35:07 GMT